Paul Schoenhagen

Paul Schoenhagen

Auto-generated profile, based on publicly available information

Paul Schoenhagen

Heart vascular thoracic institute, Cleveland Clinic, OH

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2004 in JAMA
Verified
Journal Article
Open access
PDF file
SNSteven E. Nissen
Steven E. Nissen
ETE. Murat Tuzcu
E. Murat Tuzcu
PSPaul Schoenhagen
Paul Schoenhagen
BBB. Greg Brown
B. Greg Brown
PGPeter Ganz
Peter Ganz
FIfor the REVERSAL Investigators
for the REVERSAL Investigators
In a series of pivotal clinical trials, statin drugs have been shown to reduce both atherogenic lipoproteins and cardiovascular morbidity and mortality.1-5 However, the optimal approach to lipid reduction with statins in patients with established coronary artery disease (CAD) remains uncertain. Although the efficacy of the various statins in reducing atherogenic lipoproteins and vascular inflammation varies significantly,6 the impact of these differences on clinical outcome is unknown. Because the large trials assessing morbidity and mortality were placebo controlled, they provide limited insight into differences between alternative strategies and target levels for lipid reduction. Accordingly, there is little scientific basis for recommending treatment to reduce low-density lipoprotein cholesterol (LDL-C) levels below the current recommended guidelines.7,8

5 April 2006 in JAMA
Verified
Journal Article
Open access
PDF file
SNSteven E. Nissen
Steven E. Nissen
SNStephen Nicholls
Stephen Nicholls
ISIlke Sipahi
Ilke Sipahi
PLPeter Libby
Peter Libby
JRJoel S. Raichlen
Joel S. Raichlen
FIfor the ASTEROID Investigators
for the ASTEROID Investigators
Atherosclerosis is generally viewed as a chronic, progressive disease characterized by continuous accumulation of atheromatous plaque within the arterial wall. The last 2 decades have witnessed the introduction of a variety of antiatherosclerotic therapies, most notably the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). Although statins rank among the most extensively studied therapies in contemporary medicine, the optimal target levels for low-density lipoprotein cholesterol (LDL-C) remain controversial. Recently, several active control trials have reported that more intensive statin therapy results in a greater reduction in adverse cardiovascular outcomes compared with more moderate treatment.1-3 Accordingly, guidelines now recommend achieving more aggressive target levels (an LDL-C level of <70 mg/dL [1.8 mmol/L]) in certain very high-risk secondary prevention patients.4

5 November 2003 in JAMA
Verified
Journal Article
Open access
PDF file
SNSteven E. Nissen
Steven E. Nissen
TTTaro Tsunoda
Taro Tsunoda
ETE. Murat Tuzcu
E. Murat Tuzcu
PSPaul Schoenhagen
Paul Schoenhagen
CCChristopher J. Cooper
Christopher J. Cooper
RKRichard Kerensky
Richard Kerensky
In a small village in northern Italy called Limone sul Garda live approximately 40 carriers with a naturally occurring variant of apolipoprotein A-I known as ApoA-I Milano. Individuals with ApoA-I Milano are characterized by very low levels of high-density lipoprotein cholesterol (HDL-C) (10-30 mg/dL [0.25-0.78 mmol/L]), apparent longevity,1 and much less atherosclerosis than expected for their HDL-C levels.2 The ApoA-I Milano protein differs from native ApoA-I in that cysteine is substituted at position 173 for arginine allowing disulfide-linked dimer formation. Recombinant ApoA-I Milano has been formulated in a complex with a naturally occurring phospholipid to mimic the properties of nascent HDL (ETC-216, Esperion Therapeutics, Ann Arbor, Mich). Studies in mice and rabbits with experimental atherosclerosis have demonstrated that rApoA-I Milano/phospholipid complexes rapidly mobilize cholesterol and thereby reduce atherosclerotic plaque burden. The antiatherosclerotic effects (reductions in plaque lipid and macrophage content) occur in animals as rapidly as 48 hours after a single infusion.3

6 January 2005 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
SNSteven E. Nissen
Steven E. Nissen
ETE. Murat Tuzcu
E. Murat Tuzcu
PSPaul Schoenhagen
Paul Schoenhagen
TCTim Crowe
Tim Crowe
WSWilliam J. Sasiela
William J. Sasiela
PGPeter Ganz
Peter Ganz
Recent trials have demonstrated better outcomes with intensive than with moderate statin treatment. Intensive treatment produced greater reductions in both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP), suggesting a relationship between these two biomarkers and disease progression.

22 October 2002 in Circulation
Verified
Journal Article
Closed access
PDF file
ANAnuja Nair
Anuja Nair
BKBarry D. Kuban
Barry D. Kuban
ETE. Murat Tuzcu
E. Murat Tuzcu
PSPaul Schoenhagen
Paul Schoenhagen
SNSteven E. Nissen
Steven E. Nissen
DVD. Geoffrey Vince
D. Geoffrey Vince
Background— Atherosclerotic plaque stability is related to histological composition. However, current diagnostic tools do not allow adequate in vivo identification and characterization of plaques. Spectral analysis of backscattered intravascular ultrasound (IVUS) data has potential for real-time in vivo plaque classification. Methods and Results— Eighty-eight plaques from 51 left anterior descending coronary arteries were imaged ex vivo at physiological pressure with the use of 30-MHz IVUS transducers. After IVUS imaging, the arteries were pressure-fixed and corresponding histology was collected in matched images. Regions of interest, selected from histology, were 101 fibrous, 56 fibrolipidic, 50 calcified, and 70 calcified-necrotic regions. Classification schemes for model building were computed for autoregressive and classic Fourier spectra by using 75% of the data. The remaining data were used for validation. Autoregressive classification schemes performed better than those from classic Fourier spectra with accuracies of 90.4% for fibrous, 92.8% for fibrolipidic, 90.9% for calcified, and 89.5% for calcified-necrotic regions in the training data set and 79.7%, 81.2%, 92.8%, and 85.5% in the test data, respectively. Tissue maps were reconstructed with the use of accurate predictions of plaque composition from the autoregressive classification scheme. Conclusions— Coronary plaque composition can be predicted through the use of IVUS radiofrequency data analysis. Autoregressive classification schemes performed better than classic Fourier methods. These techniques allow real-time analysis of IVUS data, enabling in vivo plaque characterization.

1 September 2013 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
AKAllan L. Klein
Allan L. Klein
SASuhny Abbara
Suhny Abbara
DADeborah A. Agler
Deborah A. Agler
CAChristopher P. Appleton
Christopher P. Appleton
CACraig R. Asher
Craig R. Asher
RWRichard D. White
Richard D. White